Appendix Table E13. Phenotypic test details in studies assessing the predictive ability of LTA in patients with ischemic heart, cerebrovascular and peripheral vascular disease

| **Author, year [ref]****UID****Country****Study Name** | **Test/Device name** **Device category Device name & manufacturer\*** | **Agonist used** | **Sample Collection and Procurement****Anticoagulant used****Interval between clopidogrel doses and blood sampling (in days)** **Interval between sampling and testing (in days):** | **Grouping of Phenotypes [Definition]**  | **Rational for the grouping of phenotypes reported (Yes/No)** **[short description]** | **Frequency of phenotypes**  |
| --- | --- | --- | --- | --- | --- | --- |
| Reny, 201222615340France and SwitzerlandADRIE | 8-channel aggregometer (TA-8V, SD Medical, Heillecourt,France) | ADP 5 and 20 µmol/L | Blood samples collected after antiplatelet therapy intake0.105 mol/L sodium citrate (1vol/9 vol)3 hrsNR | ≥55% with ADP20 µmol/L≥42% with ADP 5 µmol/L | Based on ROC curve  | ≥55%:445<55%: 204≥42%: 490<42%: 159 |